ANL-104, a treatment for degenerative obesity and diabetes, registered as a domestic patent

The domestic patent registration of ANL-104, a candidate substance for the treatment of degenerative metabolic diseases of ANLBIO Co., Ltd., was decided on January 15.'ANL-104' is a gene therapy that promotes body fat decomposition by enhancing the expression of target proteins in a way that inhibits certain microRNAs (microRNAs) that increase with aging, and is currently in the preclinical stage as a major indication of degenerative obesity and diabetes.Target proteins that increase expression by administration of 'ANL-104' are known to have excellent lipolysis effects. Through animal experiments conducted with external specialized institutions, the company confirmed that the treatment injected into the hypothalamus increased the expression of the protein, significantly reducing fat as well as weight and blood sugar, and this registered patent was filed in 2017 based on the above results of these animal tests.      With the completion of the domestic patent registration of ANL-104, a candidate for degenerative obesity and diabetes treatment, along with ANL-101, which was selected as a dementia treatment project by the Dementia Overcoming Research and Development Project in December, it is expected to gain further momentum.   Given the rapidly aging population structure, the company's medical demand for degenerative diseases such as dementia, obesity, and diabetes is expected to increase sharply in the future.We will make efforts to help ANLBIO advance the treatment of dementia diseases such as Alzheimer's disease and Parkinson's disease, as well as numerous diseases that hinder the quality of life with age, such as degenerative metabolic diseases of ANL-104.

ANL-101, Selection of Non-clinical Support Tasks for Development of Dementia Treatment by the Dementia Overcoming Research and Development Project Group

ANL-101, a candidate substance for Alzheimer's disease treatment by A&L Bio Co., Ltd., has been selected as a non-clinical task in the field of dementia treatment development by the Dementia Overcoming Research and Development Project Group (Director Muk In-hee).The research project, the first of its kind since the launch of the Dementia Overcoming Research and Development Group (hereinafter referred to as the "Project Group") under the Ministry of Health and Welfare and the Ministry of Science and ICT, is a national project directly linked to the national dementia over nine years. According to the selection of this support project, a total of 1 billion won in R&D expenses for non-clinical research and development of ANL-101 will be executed by 2023.A total of 190 companies reportedly applied for i) dementia development mechanisms, ii) dementia prediction and diagnosis, iii) dementia prevention and treatment technology development projects, and 58 tasks were supported by ANLBIO's selected dementia treatment development cost clinical tasks. In particular, the non-clinical section of dementia treatment has the highest competition rate of about 20 to 1, and ANLBIO is the only private bio company to be selected.The evaluation and selection of this project was conducted in a way that national research institutes, industry-academic cooperation groups, large hospitals, and bio companies that applied to different fields were cross-evaluated, and a very objective evaluation was made. Given that ANL-101 was selected according to the above objective evaluation procedure for the national project to overcome dementia, the technological progress and originality of ANLBIO, which is developing a treatment for Alzheimer's disease, has been confirmed through a new approach.With the selection of this assignment, all ANLBIO executives and employees will work harder to help patients and their families who are still suffering from Alzheimer's disease find a healthy daily life as soon as possible.  

The Global Dementia Overcoming Research and Development Project, under the auspices of Hanyang University, has selected an institution for the development of an improved viral delivery vector.

GenixCure Participates in '4th Next Generation Gene Therapy Vectors Summit' as the only official partner in Korea